---
title: "JINLING PHARM.: Net profit in the third quarter was 20.1248 million yuan, a year-on-year decrease of 1.84%"
description: "JINLING PHARM. announced that its revenue for the third quarter was 779 million yuan, a year-on-year decrease of 4.53%; net profit was 20.1248 million yuan, a year-on-year decrease of 1.84%. Revenue f"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262865023.md"
published_at: "2025-10-27T10:06:51.000Z"
---

# JINLING PHARM.: Net profit in the third quarter was 20.1248 million yuan, a year-on-year decrease of 1.84%

> JINLING PHARM. announced that its revenue for the third quarter was 779 million yuan, a year-on-year decrease of 4.53%; net profit was 20.1248 million yuan, a year-on-year decrease of 1.84%. Revenue for the first three quarters was 2.38 billion yuan, a year-on-year decrease of 5.95%; net profit was 68.4583 million yuan, a year-on-year decrease of 10.81%

JINLING PHARM. announced that its revenue for the third quarter was 779 million yuan, a year-on-year decrease of 4.53%; net profit was 20.1248 million yuan, a year-on-year decrease of 1.84%. Revenue for the first three quarters was 2.38 billion yuan, a year-on-year decrease of 5.95%; net profit was 68.4583 million yuan, a year-on-year decrease of 10.81%

### Related Stocks

- [000919.CN - JINLING PHARM.](https://longbridge.com/en/quote/000919.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 中际旭创：2025 年净利润 107.99 亿元，同比增长 108.81% | 中际旭创发布业绩快报，2025 年度实现营业总收入 382.4 亿元，同比增长 60.25%；净利润 107.99 亿元，同比增长 108.81%。风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的 | [Link](https://longbridge.com/en/news/277197110.md) |
| 斯马克｜10-Q：2026 财年 Q3 营收 23.39 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/277098786.md) |
| Kayne Anderson BDC｜8-K：2025 财年 Q4 营收 61.9 百万美元 |  | [Link](https://longbridge.com/en/news/277526183.md) |
| Xeris Biopharma｜8-K：2025 财年 Q4 营收 85.81 百万美元不及预期 |  | [Link](https://longbridge.com/en/news/277460784.md) |
| 南方银行｜10-K：2025 财年营收 4.19 亿美元 |  | [Link](https://longbridge.com/en/news/277251674.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.